Haozhe Xu

Changsha, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Integrin β4 drives immune evasion and therapeutic resistance to PD-1 blockade in bladder cancer via MEK/ERK signaling.

Integrin β4 drives immune evasion and therapeutic resistance to PD-1 blockade in bladder cancer via MEK/ERK signaling.

Journal: The Journal of biological chemistry

Published: May 15, 2025

ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.

ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.

Journal: British journal of cancer

Published: March 18, 2025

Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer.

Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer.

Journal: Frontiers in immunology

Published: March 05, 2025

The prognostic value of CXCR4 PET/CT imaging in unilateral primary aldosteronism patients after adrenalectomy.

The prognostic value of CXCR4 PET/CT imaging in unilateral primary aldosteronism patients after adrenalectomy.

Journal: EJNMMI research

Published: December 05, 2024

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy.

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy.

Journal: Cell reports

Published: November 03, 2024

ASO Author Reflections: Accurate and User-Friendly Models for Predicting Oncologic Outcomes Following Partial Nephrectomy in Patients with cT1-ccRCC.

ASO Author Reflections: Accurate and User-Friendly Models for Predicting Oncologic Outcomes Following Partial Nephrectomy in Patients with cT1-ccRCC.

Journal: Annals of surgical oncology

Published: June 27, 2024

Development and External Validation of Nomograms for Predicting Disease-Free Survival and Overall Survival in Patients with cT1-ccRCC After Partial Nephrectomy: A Multicenter Retrospective Study.

Development and External Validation of Nomograms for Predicting Disease-Free Survival and Overall Survival in Patients with cT1-ccRCC After Partial Nephrectomy: A Multicenter Retrospective Study.

Journal: Annals of surgical oncology

Published: April 08, 2024

Identification of molecular subtypes and diagnostic model in clear cell renal cell carcinoma based on collagen-related genes may predict the response of immunotherapy.

Identification of molecular subtypes and diagnostic model in clear cell renal cell carcinoma based on collagen-related genes may predict the response of immunotherapy.

Journal: Frontiers in pharmacology

Published: October 21, 2023

Patients with high nuclear grade pT1-ccRCC are more suitable for radical nephrectomy than partial nephrectomy: a multicenter retrospective study using propensity score.

Patients with high nuclear grade pT1-ccRCC are more suitable for radical nephrectomy than partial nephrectomy: a multicenter retrospective study using propensity score.

Journal: World journal of surgical oncology

Published: August 27, 2023

Gross Hematuria Does not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.

Gross Hematuria Does not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.

Journal: Annals of surgical oncology

Published: August 01, 2023

A Hybrid Nanoadjuvant Simultaneously Depresses PD-L1/TGF-β1 and Activates cGAS-STING Pathway to Overcome Radio-Immunotherapy Resistance.

A Hybrid Nanoadjuvant Simultaneously Depresses PD-L1/TGF-β1 and Activates cGAS-STING Pathway to Overcome Radio-Immunotherapy Resistance.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: May 09, 2023

FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C/mTOR signaling pathway.

FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C/mTOR signaling pathway.

Journal: International journal of biological sciences

Published: March 06, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026